{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:45:55Z","timestamp":1790891155956,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clim.2022.109084","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T12:29:37Z","timestamp":1659702577000},"page":"109084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Advances in the treatment of severe combined immunodeficiency"],"prefix":"10.1016","volume":"242","author":[{"given":"Mary A.","family":"Slatter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Gennery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clim.2022.109084_bb0005","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2013.09.044","article-title":"Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the primary immune deficiency treatment consortium experience","volume":"133","author":"Shearer","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"Aziz","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0015","doi-asserted-by":"crossref","first-page":"15061","DOI":"10.1038\/nrdp.2015.61","article-title":"Severe combined immunodeficiencies and related disorders","volume":"1","author":"Fischer","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clim.2022.109084_bb0020","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2022.109084_bb0025","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(69)92112-6","article-title":"Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency","volume":"1","author":"De Koning","year":"1969","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clim.2022.109084_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2014.9132","article-title":"Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States","volume":"312","author":"Kwan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2022.109084_bb0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3389\/fimmu.2017.01448","article-title":"First year of Israeli newborn screening for severe combined immunodeficiency: clinical achievements and insights","volume":"8","author":"Rechavi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10875-016-0347-5","article-title":"Newborn screening for severe primary immunodeficiency diseases in Sweden: a 2-year pilot TREC and KREC screening study","volume":"37","author":"Barbaro","year":"2017","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0045","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clim.2017.05.007","article-title":"An evaluation of the TREC assay with regard to the integration of SCID screening into the Dutch newborn screening program","volume":"180","author":"Blom","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jpc.13659","article-title":"Newborn screening for severe combined immunodeficiency: evaluation of a commercial T-cell receptor excision circle-based method in Victorian dried blood spots","volume":"54","author":"Richards","year":"2018","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.clim.2022.109084_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2019.03.012","article-title":"Clinical and economic aspects of newborn screening for severe combined immunodeficiency: depistrec study results","volume":"202","author":"Thomas","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0060","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3389\/fimmu.2019.02406","article-title":"First universal newborn screening program for severe combined immunodeficiency in Europe: two-years\u2019 experience in Catalonia (Spain)","volume":"10","author":"Argudo-Ram\u0131rez","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2022.109084_bb0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/hum.1993.4.4-521","volume":"4","author":"Blaese","year":"1993","journal-title":"Hum. Gene Ther."},{"issue":"5466","key":"10.1016\/j.clim.2022.109084_bb0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.clim.2022.109084_bb0075","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2022.109084_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.gendis.2019.07.007","article-title":"Gene therapy and genome editing for primary immunodeficiency diseases","volume":"7","author":"Zhang","year":"2020","journal-title":"Genes Dis."},{"issue":"9","key":"10.1016\/j.clim.2022.109084_bb0085","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer","volume":"25","author":"Pike-Overzet","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2022.109084_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtm.2019.08.014","article-title":"Biosafety studies of a clinically applicable lentiviral vector for the gene therapy of artemis-SCID","volume":"15","author":"Charrier","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.clim.2022.109084_bb0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/bs.pmbts.2021.03.001","article-title":"Targeted genome editing for the correction or alleviation of primary immunodeficiencies","volume":"182","author":"Sipe","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"17","key":"10.1016\/j.clim.2022.109084_bb0100","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clim.2022.109084_bb0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10875-018-0540-9","article-title":"Long-term health outcome and quality of life post-HSCT for IL7R\u03b1-, Artemis-, RAG1- and RAG2-deficient severe combined immunodeficiency: a single center report","volume":"38","author":"Abd Hamid","year":"2018","journal-title":"J. Clin. Immunol."},{"issue":"15","key":"10.1016\/j.clim.2022.109084_bb0110","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2016-11-748616","article-title":"Long-term outcome of hematopoietic stem cell transplantation for IL2RG\/JAK3 SCID: a cohort report","volume":"129","author":"Abd Hamid","year":"2017","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clim.2022.109084_bb0115","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.109084_bb0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clim.2022.109084_bb0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J. Clin. Immunol."},{"issue":"26","key":"10.1016\/j.clim.2022.109084_bb0130","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1182\/blood-2011-06-362533","article-title":"IL-21 is the primary common \u03b3 chain-binding cytokine required for human -differentiation in vivo","volume":"118","author":"Recher","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.109084_bb0135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.iac.2010.01.002","article-title":"Bone marrow transplantation and alternatives for adenosine deaminase deficiency","volume":"30","author":"Gaspar","year":"2010","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"2","key":"10.1016\/j.clim.2022.109084_bb0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaci.2020.10.020","article-title":"SCID newborn screening: What we\u2019ve learned","volume":"147","author":"Currier","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"14","key":"10.1016\/j.clim.2022.109084_bb0145","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2016-11-749721","article-title":"United Kingdom paediatric bone marrow transplant group. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant","volume":"129","author":"Hiwarkar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.109084_bb0150","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clim.2022.109084_bb0155","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jcyt.2018.03.040","article-title":"Multicenter phase 1\/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation","volume":"20","author":"Ip","year":"2018","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0160","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0165","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaci.2014.08.019","article-title":"CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: a preliminary study","volume":"135","author":"Touzot","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2022.109084_bb0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41409-017-0035-y","article-title":"Low-dose donor memory T-cell infusion after TCR alpha\/beta depleted unrelated and haploidentical transplantation: results of a pilot trial","volume":"53","author":"Maschan","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"18","key":"10.1016\/j.clim.2022.109084_bb0175","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"S3","key":"10.1016\/j.clim.2022.109084_bb0180","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.bbmt.2018.12.080","article-title":"Administration of BPX-501 cells following \u03b1\u03b2 T and B-cell-depleted HLA-Haploidentical HSCT (haplo-HSCT) in children with malignant or non-malignant disorders","volume":"25","author":"Galaverna","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.clim.2022.109084_bb0185","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2022.109084_bb0190","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jaci.2021.10.017","article-title":"Advances in hematopoietic stem cell transplantation in severe combined immunodeficiency: a report on the SCETIDE 2006-2014 European cohort","volume":"149","author":"Lankester","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbmt.2013.11.005","article-title":"Low dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies","volume":"20","author":"Lane","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2022.109084_bb0200","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2141.2011.08994.x","article-title":"Omission of in vivo T-cell depletion promotes rapid expansion of na\u00efve CD4. Cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant","volume":"156","author":"Chiesa","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0205","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41409-020-01152-2","article-title":"Improved survival and graft function in ex vivo T-cell depleted haploidentical hematopoietic cell transplantation for primary immunodeficiency","volume":"56","author":"Lum","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2022.109084_bb0210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10875-022-01239-z","article-title":"TCR\u03b1\u03b2-depleted haploidentical grafts are a safe alternative to HLA-matched unrelated donor stem cell transplants for infants with severe combined immunodeficiency","volume":"42","author":"Tsilifis","year":"2022","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2022.109084_bb0215","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2017.25","article-title":"Andersson BS. Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome","volume":"52","author":"Kreetapirom","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10875-016-0293-2","article-title":"Successful haploidentical stem cell transplantation with post-transplant cyclophosphamide in a severe combined immune deficiency patient: a first report","volume":"36","author":"Ouederni","year":"2016","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2022.109084_bb0225","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children","volume":"25","author":"Neven","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.clim.2022.109084_bb0230","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.3324\/haematol.2018.215285","article-title":"Albert MH.T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors","volume":"104","author":"Kurzay","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clim.2022.109084_bb0235","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10875-019-00600-z","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in South India","volume":"39","author":"Uppuluri","year":"2019","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0240","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood.2021014654","article-title":"Milieu int\u00e9rieur consortium. Defects in mucosal immunity and nasopharyngeal dysbiosis in HSC transplanted SCID patients with IL2RG\/JAK3 deficiency","volume":"139","author":"Goncalves","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.109084_bb0245","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","article-title":"Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience","volume":"24","author":"Slatter","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2022.109084_bb0250","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clim.2022.109084_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.09.018","article-title":"Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: a prospective multicenter study","volume":"28","author":"van der Stoep","year":"2022","journal-title":"Transplant. Cell Ther."},{"issue":"2","key":"10.1016\/j.clim.2022.109084_bb0260","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/pbc.25267","article-title":"Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning","volume":"62","author":"Dinur-Schejter","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.clim.2022.109084_bb0265","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after busulphan compared to treosulphan in children and adolescents undergoing allogeneic haematopoietic stem cell transplantation. On behalf of pediatric and transplant-related complications and quality of life EBMT working parties","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.clim.2022.109084_bb0270","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bbmt.2019.03.008","article-title":"Low exposure busulfan conditioning to achieve sufficient multilineage chimerism in patients with severe combined immunodeficiency","volume":"25","author":"Dvorak","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.clim.2022.109084_bb0275","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaci.2017.02.036","volume":"141","author":"Slack","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2022.109084_bb0280","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s10875-015-0186-9","volume":"35","author":"Wolska-Ku\u015bnierz","year":"2015","journal-title":"J. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2022.109084_bb0285","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10875-020-00811-9","article-title":"Treosulfan-based conditioning regimen in haematopoietic stem cell transplantation with TCR\u03b1\u03b2\/CD19 depletion in nijmegen breakage syndrome","volume":"40","author":"Laberko","year":"2020","journal-title":"J. Clin. Immunol."},{"issue":"9693","key":"10.1016\/j.clim.2022.109084_bb0290","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0140-6736(09)60945-4","article-title":"Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1\/2 study","volume":"374","author":"Straathof","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2022.109084_bb0295","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.bbmt.2018.12.172","article-title":"Toxicity-free hematopoietic stem cell engraftment achieved with anti-CD117 monoclonal antibody conditioning","volume":"25","author":"Agarwal","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0300","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.blre.2016.04.007","article-title":"Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: another step forward","volume":"30","author":"Ali","year":"2016","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0305","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clim.2022.109084_bb0310","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1182\/blood-2010-06-284349","article-title":"Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases","volume":"117","author":"Schulz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.109084_bb0315","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3389\/fimmu.2017.00798","article-title":"Natural killer cells from patients with recombinase-activating gene and non-homologous end joining gene defects comprise a higher frequency of CD56bright NKG2A+++ cells, and yet display increased degranulation and higher perforin content","volume":"8","author":"Dobbs","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0320","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4 + immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.clim.2022.109084_bb0325","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.109084_bb0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08880018.2020.1868637","article-title":"Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity","volume":"38","author":"Mozo","year":"2021","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.clim.2022.109084_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28968","article-title":"\u03b14\u03b27 integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease","volume":"68","author":"Ibrahimova","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"issue":"6","key":"10.1016\/j.clim.2022.109084_bb0340","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41409-020-01188-4","article-title":"Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD","volume":"56","author":"Mehta","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0345","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s10875-021-00991-y","article-title":"Thymopoiesis, alterations in dendritic cells and tregs, and reduced T cell activation in successful extracorporeal photopheresis treatment of GVHD","volume":"41","author":"Flinn","year":"2021","journal-title":"J. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2022.109084_bb0350","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/jca.21700","article-title":"An automated mini buffy coat preparation method for use in mini extracorporeal photopheresis treatment of graft-vs-host-disease in a low body weight pediatric patient","volume":"34","author":"Matic","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.clim.2022.109084_bb0355","doi-asserted-by":"crossref","first-page":"101524","DOI":"10.1016\/j.trim.2021.101524","article-title":"Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to graft versus host disease management","volume":"71","author":"Mirfakhraie","year":"2022","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0360","doi-asserted-by":"crossref","first-page":"761616","DOI":"10.3389\/fimmu.2021.761616","article-title":"Mesenchymal stromal cells for the treatment of graft versus host disease","volume":"12","author":"Kelly","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0365","doi-asserted-by":"crossref","first-page":"100883","DOI":"10.1016\/j.blre.2021.100883","article-title":"Putting function back in dysfunction: Endothelial diseases and current therapies in hematopoietic stem cell transplantation and cellular therapies","volume":"51","author":"Sumransub","year":"2022","journal-title":"Blood Rev."},{"issue":"13","key":"10.1016\/j.clim.2022.109084_bb0370","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0375","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the paediatric diseases and inborn errors working parties of the European society of blood and marrow transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.clim.2022.109084_bb0380","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bbmt.2017.04.026","volume":"23","author":"Heimall","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.clim.2022.109084_bb0385","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaip.2021.11.032","article-title":"Long-term clinical outcomes of severe combined immunodeficiency patients given nonablative marrow transplants","volume":"10","author":"Hardin","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.clim.2022.109084_bb0390","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(04)16457-X","article-title":"Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency","volume":"363","author":"Laffort","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2022.109084_bb0395","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jaci.2014.07.009","article-title":"Severe cutaneous human papillomavirus infection associated with natural killer cell deficiency following stem cell transplantation for severe combined immunodeficiency","volume":"134","author":"Kamili","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2022.109084_bb0400","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/cei.13068","article-title":"Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy","volume":"191","author":"Stubbs","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0405","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2022.109084_bb0410","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41409-020-0866-9","article-title":"Anti-Mullerian hormone and inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens","volume":"55","author":"Leiper","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.clim.2022.109084_bb0415","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clim.2022.109084_bb0420","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2020010260","article-title":"Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency","volume":"138","author":"Reinhardt","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clim.2022.109084_bb0425","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"411","key":"10.1016\/j.clim.2022.109084_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.clim.2022.109084_bb0435","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/s41467-019-10080-9","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.clim.2022.109084_bb0440","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10875-021-00989-6","article-title":"Gene editing rescues in vitro T cell development of RAG2-deficient induced pluripotent stem cells in an artificial thymic organoid system","volume":"41","author":"Gardner","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0445","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2004.10.012","article-title":"Development of population-based newborn screening for severe combined immunodeficiency","volume":"115","author":"Chan","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.109084_bb0450","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/bloodadvances.2017010835","article-title":"Neurologic event\u2013free survival demonstrates a benefit for SCID patients diagnosed by newborn screening","volume":"1","author":"Dvorak","year":"2017","journal-title":"Blood Adv."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:06:56Z","timestamp":1761494816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":90,"alternative-id":["S1521661622001656"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.109084","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of severe combined immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.109084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109084"}}